Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

CytomX Therapeutics (CTMX) Receivables - Net (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Receivables - Net for 12 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables - Net fell 51.4% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2025, down 51.4%, and an annual FY2024 reading of $3.1 million, down 9.59% over the prior year.
  • Receivables - Net was $1.6 million for Q3 2025 at CytomX Therapeutics, down from $1.9 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $36.0 million in Q4 2022 and bottomed at $756000.0 in Q1 2021.
  • Average Receivables - Net over 5 years is $4.2 million, with a median of $1.9 million recorded in 2025.
  • The sharpest move saw Receivables - Net tumbled 99.42% in 2021, then skyrocketed 4455.19% in 2022.
  • Year by year, Receivables - Net stood at $790000.0 in 2021, then surged by 4455.19% to $36.0 million in 2022, then plummeted by 90.46% to $3.4 million in 2023, then fell by 9.59% to $3.1 million in 2024, then tumbled by 47.5% to $1.6 million in 2025.
  • Business Quant data shows Receivables - Net for CTMX at $1.6 million in Q3 2025, $1.9 million in Q2 2025, and $2.0 million in Q1 2025.